RT Journal Article SR Electronic T1 Lung cancer screening - what does it mean for our practice? JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 4172 DO 10.1183/13993003.congress-2020.4172 VO 56 IS suppl 64 A1 Claire Calderwood A1 Erik Skyllberg A1 Kiran Desai A1 Mohammad Moghal A1 Rajesh Banka YR 2020 UL http://erj.ersjournals.com/content/56/suppl_64/4172.abstract AB Rationale: The benefits of low-dose computed tomography (LDCT) screening for lung cancer are clear. To understand the service implications for a district general hospital, we evaluated the proportion of our patients who may have been identified through screening.Methods: Patients with a lung cancer diagnosis were identified from registry (April 17-March 19). Data were extracted from registry and health record review. Patients with recorded smoking history and likely or confirmed lung carcinoma or mesothelioma were included. Descriptive analyses were conducted and the proportion eligible for LDCT screening under major trial inclusion criteria calculated.Results: 703 patients were identified; 448 were included. 48% were female; median age was 72 (IQR 65-79 years). 34.6% and 50.2% were current or ex-smokers. Among ex-smokers median years since smoking was 13 (IQR 4-30). Among ever-smokers median pack years was 40 (IQR 25-50). 73.4% of primary lung carcinomas with staging data available were stage 3-4 at diagnosis. Based on NLST and NELSON criteria, 31% and 24% of our patients would have been eligible for LDCT one year prior to diagnosis. It was not possible to calculate the Liverpool Lung Project risk score from available data, however 61% of our population would have been approached for risk stratification under UKLS. Assuming CT abnormalities were present two years prior to diagnosis, similar proportions were eligible for screening.Conclusions: Approximately 1/3 of our population would be invited for screening according to NLST and NELSON criteria; a significant proportion of lung cancer cases would therefore not be detected via this approach. Additional tools to stratify risk and facilitate earlier diagnosis are needed.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4172.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).